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single items slightly worse than CG. Karnofsky-Index showed 
comparable high values (median of 90%). QLQ-PR25 re-
vealed more PCa-related symptoms for ADT patients. Within 
6 months, median PSA level declined >90% and median tes-
tosterone levels declined below castration level from 4.0 to 
0.2 ng/mL. Clinical response (European Organisation for Re-
search and Treatment of Cancer criteria) was observed in at 
least 90% of ADT patients. Conclusions: Long-term ADT with 
LAM is a well-accepted, tolerated, effective, and low-burden 
treatment option for patients with advanced, hormone-sen-
sitive PCa. © 2017 S. Karger AG, Basel
Introduction
Prostate cancer (PCa) is the most prevalent cancer and 
the third-leading cause of cancer-related death in men, 
with an estimated 60,000 new cases and 13,000 deaths an-
nually in Germany [1]. With a mean age for disease onset 
of 71 years, PCa is typically identified as an “old man’s” 
disease. The difference between disease incidence and 
mortality is currently rising since the age-standardized 
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Abstract
Introduction: We investigated the health-related quality of 
life (HRQoL) of long-term prostate cancer patients who re-
ceived leuprorelin acetate in microcapsules (LAM) for andro-
gen-deprivation therapy (ADT). Methods: The observational 
study was carried out by 30 office-based German urologists 
in 536 prostate cancer (PCa) patients treated for ≥5 years 
with LAM and in 116 patients of an age-matched control 
group (CG). Data on HRQoL and health status was collected 
prospectively using validated questionnaires QLQ-C30, 
QLQ-PR25 and Karnofsky Index. Data on effectiveness (clini-
cal response, prostate specific antigen [PSA], testosterone) 
and safety was collected retrospectively from patients’ 
health records. We used descriptive statistics to analyze the 
data. Results: The mean treatment duration was 8.6 years 
(range 4.5–19.8 years). General health status (QLQ-C30) was 
comparable for both groups. Differences were observed re-
garding physical – and role functioning. ADT patients rated 
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mortality rate was decreasing during the last 20 years. On 
the other hand, an increase in early disease stages was ob-
served, most likely due to the constantly increasing use of 
the prostate-specific antigen (PSA) for early detection [2].
Treatment of PCa has improved over the last decades 
to an extent that in a majority of patients in an early stage, 
PCa can be considered a curable disease; in a recurrent 
and advanced or metastatic stage, PCa can be considered 
a long-term surviving disease. Among the initial thera-
peutic regimens, androgen-deprivation therapy (ADT) 
has been the preferred treatment in advanced PCa for 70 
years [3, 4]. Recent therapeutic options, such as CYP17 
inhibitors or novel androgen-receptor blockers in pre- or 
post-chemo setting as well as a combined chemo-hor-
mone therapy in the subgroup of hormone-sensitive, 
newly diagnosed, metastatic PCa essentially use ADT as 
backbone-therapy [2]. In order to achieve androgen de-
privation, surgical or medical castration and the use of 
antiandrogens were the 2 methods of choice [5].
Since the beginning of the 1990s, LHRH agonists, the 
predominant form of medical ADT, have been used to 
treat advanced and hormone-sensitive PCa [5]. LHRH 
agonists decrease testosterone levels to the castration lim-
it within 3–4 weeks after a short initial increase known as 
“flare-up” effect [6–8]. A good tumor control with suffi-
cient response rates and patients’ treatment acceptance 
mainly depends on the functional well-being and issues 
of health-related quality of life (HRQoL) among the con-
stantly rising sample of long-term PCa survivors.
Thus, in our study on HRQoL we investigated leupro-
relin acetate in microcapsules (LAM), an established 
LHRH agonist used as first-line treatment in advanced 
PCa [9, 10]. LAM is the most widely prescribed ADT in 
Germany, is marketed since 1991, and is therefore well 
suited to assess the status of long-term ADT survivors. 
However, relatively little is known about such survivors 
and neither HRQoL nor the maximum time period dur-
ing which the tumor can be controlled using ADT has 
been shown in an office-based setting reflecting daily 
practice.
Methods
Design
This non-interventional study was performed as a combined 
retrospective and prospective long-term data collection in accor-
dance with the German drug law §67 section 6. The study provid-
ed data collected prospectively during the individual last (i.e., cur-
rent) visit of each considered patient including demographics, 
HRQoL-questionnaires, and therapeutic contentment as well as 
retrospectively concerning the historic development of efficacy 
and safety variables. Data collection started on August 15, 2011 
and ended on October 9, 2012, covering a documentation period 
between June 10, 1992 and June 11, 2012. The study is registered 
in the study registry of the German Association of Research-based 
Pharmaceutical Companies (vfA) under the unique Study No.: 
ENA E005/DE-N-LEU-019.
Patients and Sites
Data of 536 patients from 30 German urologic sites with ad-
vanced and hormone-sensitive PCa was collected after ADT with 
subcutaneous LAM for at least 5 years of therapy. In addition, data 
of 116 cancer- and ADT-free age-matched urological patients (age 
≥77 years) served as controls. Patient selection was at the discretion 
of the treating physician. Each site provided data records for 8–20 
PCa patients and for up to 4 patients of the control group (CG).
Data Collection
Data was collected and processed under strictly pseudonymous 
conditions. Tumor-related data such as clinical response, PSA, and 
testosterone levels were collected retrospectively over 6-month 
time intervals only for PCa patients (n = 536). Baseline demo-
graphics with Karnofsky Index and the HRQoL data was docu-
mented for both the PCa patients (n = 536) and the CG (n = 116) 
at the current (prospective) visit. In order to achieve robust HRQoL 
data, we used the standardized and validated European Organisa-
tion for Research and Treatment of Cancer quality-of-life ques-
tionnaire QLQ-C30 and the disease specific questionnaire module 
QLQ-PR25 [11].
In these questionnaires, related questions were to be answered 
on 4 possibilities or on a visual analogue scale from 1 to 7. For 
evaluation, the questions were summarized in groups to calculate 
sum scores for the different sub-scales. These sub-scores were then 
to be transformed mathematically into final results between 0 and 
100, presenting 100 as the best value for all functional scores und 
as the worst result for all symptom scores.
Statistics
Data of all patients was analyzed using descriptive statistics in 
an exploratory manner. Missing data was marked as such. Safety 
was evaluated according to the number and severity of adverse 
events and adverse drug reactions based on MedDRA terminology 
version 15.0.
Ethical Principles
The study was conducted in accordance with the Declaration 
of Helsinki and announced at the Federal Institute for Drugs and 
Medical Devices (BfArM), the National Association of Statutory 
Health Insurance Physicians (KBV), and the National Association 
of Statutory Health Insurance Funds (GKV Spitzenverband). All 
patients provided a signed written informed consent.
Results
Baseline Characteristics
The initially treated study set consisted of 540 patients 
diagnosed with PCa. Since treatment duration of 4 (0.7%) 
patients was below 5 years of treatment, they were not 
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considered for evaluation. Thus, HRQoL, effectiveness, 
acceptance, safety and local tolerability were recorded for 
the remaining 536 patients treated with LAM for at least 
5 years. For the separately recruited age-matched CG, a 
sample of 116 cancer- and ADT-free patients was consid-
ered.
Baseline demographics was recorded at the current 
visit for both the PCa patients and the CG without rele-
vant differences between the 2 patient sets. Mean age ± 
SD (79.6 ± 6.3 vs. 80.5 ± 3.1 years), height, weight, and 
BMI were comparable between the 2 patient sets as was 
the Karnofsky-Index (88.0 ± 12.7 vs. 88.4 ± 12.0; Ta-
ble 1).
The age of the PCa patients ranged between 48 and 98 
years, with the largest group being in the age range 71 to 
85 years (n = 463, 71.6%). Most of the 536 treated PCa 
patients received therapy with LAM as monotherapy 
(322/60.1%), followed by combinations with antiandro-
gens (bicalutamide, flutamide, cyproteron acetate; 
163/30.4%), combination with radiation (27/5.0%) and 
combinations with others (24/4.5%). Moreover, LAM 
treatment was recognized as first-line therapy in 349 pa-
tients (65.1%), after radical prostatectomy (RP) in 163 
patients (30.4%), and after radiation therapy in 75 pa-
tients (14.0%; multiple remarks possible). The time be-
tween diagnosis of PCa and the onset of LAM therapy did 
not exceed 1 month for about half of the 536 PCa patients 
(median 1.0). Before start of LAM therapy, 333 out of 536 
PCa patients (62.1%) were found to be with comorbidi-
ties such as hypertension (36.4%), coronary heart disease 
(17.5%), benign prostatic hyperplasia (15.1%), diabetes 
(11.2%) and cardiac insufficiency (7.5%; again multiple 
remarks possible). The mean total duration of treatment 
with LAM in this study was 8.6 years (SD 2.9, median: 
8.0, maximum 19.8 years), resulting in a total of 4,610 
patient treatment-years. The categorized duration of 
LAM therapy during the study period is displayed in 
 Table 2.
Health-Related Quality of Life
Assessment of the general health status according to 
QLQ-C30 revealed a mean of 64.6 ± 20.5 (median: 66.7) 
for LAM-treated patients versus 66.8 ± 20.3 (median: 
66.7) for the age-matched CG (p = 0.3117; 100 = best; 
Fig. 1a). This trend with comparable results between CG 
and PCa patients can be observed for the QLQ-C30 func-
tional scores (100 = best) and most of the symptom scores 
(100 = poor). Marginal differences were seen for physical 
functioning (73.2 ± 23.1 PCa vs. 78.1 ± 21.0 control; p = 
0.0402) and role functioning (70.6 ± 30.4 vs. 74.4 ± 25.7; 
p = 0.1648; Fig. 1a). The symptoms fatigue (33.6 ± 25.1 vs. 
28.8± 23.3; p = 0.0629), dyspnoea (24.0 ± 28.5 vs. 19.6 ± 
26.9; p = 0.1307) and insomnia (28.9 ± 32.6 vs. 23.7 ± 27.2; 
p = 0.0751) were also assessed to be slightly inferior in 
PCa patients (Fig. 1b).
Evaluation of the prostate-specific QLQ-PR25 showed 
a worse status regarding sexual activity (12.0 ± 20.6 vs. 
23.7 ± 25.7; p < 0.0001) and sexual functioning (43.3 ± 
25.8 vs. 55.9 ± 27.0; p = 0.0067) for PCa patients (100 = 
best; Fig. 1c). Results of the QLQ-PR25 symptom scores 
(100 = poor; Fig.  1d) displayed that PCa patients had 
slightly less urinary symptoms (28.2 ± 19.8 vs. 31.2 ± 19.2; 
p = 0.1472). Symptoms of androgen suppression were 
clearly more pronounced in PCa patients (21.4 ± 17.3 vs. 
Table 1. Demographic characteristics
Parameter* LAM therapy (n = 536) Control group (n = 116)
Age, years 79.6±6.3 (80.0; n = 536) 80.5±3.1 (80.0; n = 116)
Height, cm 174.2±6.3 (174; n = 476) 174.7±5.6 (174.0; n = 115)
Weight, kg 83.1±12.6 (82.0; n = 472) 82.2±10.6 (81.0; n = 112)
BMI, kg/m2 27.3±3.7 (26.8; n = 472) 26.9±3.1 (26.5; n = 111)
Karnofsky-index, % 88.0±12.7 (90.0; n = 522) 88.4±12.0 (90.0; n = 114)
* Mean ± SD; values in brackets denotes median and individual case number.
Table 2. Duration of LAM therapy
Categories of treatment 
duration in years
Patients overall 
(n = 536), n (%)
≥5 until <6 years 120 (22.4)
At least 6 until <7 years 90 (16.8)
At least 7 until <9 years 114 (21.3)
At least 9 until <10 years 39 (7.3)
At least 10 until <12 years 101 (18.8)
≥12 years* 72 (13.4)
* Maximum duration of LAM therapy was 19.8 years.
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10.8 ± 13.2; p < 0.0001), and PCa patients also had a high-
er need of incontinence assistance (29.6 ± 34.2 vs. 16.7 ± 
20.5; p = 0.0056). However, 163 of the 536 PCa patients 
had previously undergone RP.
Continuously high values were reported in a major-
ity of patients for the Karnofsky-Index (median of 90% 
for both PCa patients and the CG; Table 1). With an In-
dex of ≥70% in about 80% of PCa patients and patients 
of the CG, the overall patients’ performance status 
therefore indicated a long-term clinically stable condi-
tion.
In addition, constantly high ratings of “excellent” and 
“good” in at least more than 95% of the PCa patients were 
observed for the physicians’ assessments of treatment 
regimen, tolerability of LAM treatment, and handling of 
the used syringe.
Effectiveness
The clinical response to LAM therapy as assessed by 
the treating physician using an overall clinical rating sup-
ported by investigational and laboratory results (e.g., 
TRUS, DRE, PSA, testosterone) could be documented in 
at least about 90% of the PCa patients during a treatment 
period of up to about 20 years (resulting mean of 8.6 years, 
median of 8.0 years, and maximum of 19.8 years).
In general, the clinical response (i.e., either stable dis-
ease or partial/complete remission) remained high dur-
ing the entire observation period with still over 90% at the 
current visit.
Median PSA levels decreased by >90% within the 
first  6 months after start of LAM therapy (from 8.1 to 
0.4  ng/mL) and stayed below this level for up to 13 
years. The median PSA value at the current visit was still 
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Fig. 1. a–d Overall results of quality of life assessment by European 
Organisation for Research and Treatment of Cancer Question-
naires QLQ-C30 and QLQ-PR25. The Quality of Life Question-
naire categorized answers between 1 and 4 or 1 and 7 (1 = no symp-
tom) were transformed according to the QLQ scoring manuals 
into values between 0 (= no symptom) and 100. One hundred is 
defined as the best result for functional scores and the worst result 
for symptom scores.
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0.3 ng/mL. Also, well within the first 6 months of therapy, 
median testosterone levels were suppressed from 4.0 to 
0.2 ng/mL and were therefore below the castration level 
of <0.5 ng/mL. During 13 years of therapy, the median 
testosterone levels remained constantly below the castra-
tion level with a median value of 0.15 ng/mL in year 13 
and at the current visit.
Safety and Tolerability
Adverse events occurred in 96 (17.9%) of the 536 treat-
ed PCa patients, with adverse drug reactions (ADRs) in 
64 (11.9%) of these patients (i.e., 0.014 ADRs per treat-
ment year) and hot flushes as the most frequently report-
ed ADRs. Serious adverse events (SAEs) were recorded in 
11 (2.1%) of the patients (mainly hot flushes and hyper-
hidrosis). The detailed numbers of patients with adverse 
events, SAEs, and ADRs are provided in Table 3. During 
the time of treatment observation, no relevant abnormal-
ities were observed regarding lab results with hemoglo-
bin, creatinine, HbA1c, glucose, GOT, GPT, γ-GT, LDH, 
cholesterol, HDL and AP.
Discussion
The present observational study can be categorized 
as one of few studies investigating ADT over a very 
long  period of time providing treatment durations of 
up  to about 20 years. At the end of this observation-
al   period, results on HRQoL and Karnofsky-Index 
were collected as a special feature at one current, pro-
spective visit from 536 PCa patients and were compared 
with an age-matched CG of 116 cancer- and ADT-free 
urological patients. In general, what is most important 
for treatment success in long-term therapies is the toler-
ability of medication and acceptance of therapy. Thus, 
the collection of data on HRQoL will have a great influ-
ence on the additional assessment of possible therapeu-
tic regimens. For the choice of appropriate treatment 
options not only the course of effectiveness-related vari-
ables like tumor remission, PSA, and testosterone levels 
have to be considered but also the different aspects of 
HRQoL, in particular, the known and partially very de-
manding complications of an advanced PCa therapy 
such as sexual, urological and intestinal dysfunctions [5, 
10, 12–15]. A limitation of this study is the retrospective 
data collection of data on efficacy, safety and tolerabil-
ity during the long-term treatment phase for the PCa 
patients.
Regarding the achieved study results, tumor control 
and overall HRQoL with patients’ general physical condi-
tion and health status were remarkably well balanced be-
tween the PCa patients and the CG, which is in line with 
previous studies [10, 12]. In addition, single aspects of 
HRQoL as well as of the Karnofsky-Index in long-term 
PCa survivors were within the range of the outcome in the 
CG representing age-matched but cancer-free, urological 
patients.
However, as also seen in other trials, sexual activity 
and sexual functioning were clearly more affected in PCa 
patients receiving long-term ADT [15, 16], thus showing 
better sexual activity (p < 0.0001) and sexual functioning 
(p = 0.0067) in the CG. As expected for the PCa patients 
due to prior ADT and RP, respectively, the symptom 
scores “hormonal withdrawal” (p < 0.0001) and “inconti-
nence assistance” (p = 0.0056) revealed pertinent current 
results.
Nevertheless, the success of ADT in advanced PCa is 
also defined by response (complete remission, or partial 
remission, or stable disease), decrease of PSA levels, and 
effective testosterone suppression down to the castration 
limit or below [5, 13]. In respect of these parameters, the 
present data collection revealed that therapy with LAM in 
long-term PCa survivors treated for up to a maximum of 
about 20 years proved effective. In other studies, much 
shorter ADT treatment durations (most frequently over 
around 1 year) have been investigated. LAM was investi-
gated in a randomized, open-label European multicentre 
study with 296 patients over a 12-month period. After 
12 months’ therapy with the 6-month depot, a median 
PSA reduction of 89% to 0.3 ng/mL was observed, and 
median serum testosterone levels were suppressed below 
0.2 ng/mL (0.15 ng/mL) [10]. 
A European Organisation for Research and Treatment 
of Cancer study investigated whether short-term andro-
Table 3. Adverse events and adverse drug reactions
LAM therapy
(n = 536), n (%)
Patients with AEs 96 (17.9)
Patients with SAEs 11 (2.1)
Patients with AEs, not classified as ADRs 44 (8.2)
Patients with ADRs
Mild
Moderate
Severe
64 (11.9)
26 (4.9)
34 (6.3)
4 (0.7)
AE, adverse event; SAE, serious adverse event; ADR, adverse 
drug reaction.
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gen suppression plus radiation is not inferior to long-
term androgen deprivation therapy [14]. After a 5-year 
follow-up, long-term androgen suppression showed an 
advantage regarding overall mortality (15.2%) compared 
to the short-term group (19.0%).
With regard to safety, tolerability and acceptance of 
the long-term ADT-therapy, the results adequately 
 support previous findings in terms of the known safe-
ty  profile for LAM with hot flushes as the most freq-
uently reported ADRs and only a small number of 
ADRs  in summary (64/536 patients, 11.9%; 4,610 pa-
tient treatment years; i.e., 0.014 ADRs per year). Hot 
flushes are a common side effect of LHRHa treatment 
and are reported in a higher proportion of patients in 
prospective trials [17–20]. In our study, we selected pa-
tients receiving at least 5 years of LHRHa treatment. Pa-
tients who discontinued treatment due to side effects are 
not investigated in this cohort. The consistently high 
values for the Karnofsky-Index and the physicians’ as-
sessments of treatment regimen, local tolerability and 
handling of the syringe also indicated long-term clini-
cally stable conditions for the overall health status of the 
PCa patients.
Conclusion
The vast majority of the long-term surviving PCa-pa-
tients treated with LAM as ADT in this non-intervention-
al data collection provided a very stable general health 
status that was comparable to current cancer- and ADT-
free urological patients. These surprisingly good results 
were achieved despite the known bias concerning not re-
corded drop-outs in retrospective trials. This is supported 
by a constantly high outcome of data on HRQoL and 
 Karnofsky-Index after a therapy with LAM of up to al-
most 20 years in the PCa patients. In addition, effective-
ness results regarding the course of clinical response, tes-
tosterone suppression and PSA reduction were as expect-
ed during the retrospective treatment period.
In summary, long-term ADT with LAM is a well-ac-
cepted, tolerated, effective and low-burden treatment 
option for patients with advanced, hormone-sensitive 
PCa.
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